دورية أكاديمية
[The pharmacokinetics of monoclonal antibodies].
| العنوان: | [The pharmacokinetics of monoclonal antibodies]. |
|---|---|
| عنوان ترانسليتريتد: | Farmacokinetiek van monoklonale antilichamen. |
| المؤلفون: | Keizer RJ; Slotervaartziekenhuis, Ziekenhuisapotheek, Postbus 90.440, 1006 BK Amsterdam. aprke@slz.nl, Huitema AD, Damen CW, Schellens JH, Beijnen JH |
| المصدر: | Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2007 Mar 24; Vol. 151 (12), pp. 683-8. |
| نوع المنشور: | English Abstract; Journal Article; Review |
| اللغة: | Dutch; Flemish |
| بيانات الدورية: | Publisher: Vereniging NTvG Country of Publication: Netherlands NLM ID: 0400770 Publication Model: Print Cited Medium: Print ISSN: 0028-2162 (Print) Linking ISSN: 00282162 NLM ISO Abbreviation: Ned Tijdschr Geneeskd Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017?-: Amsterdam : Vereniging NTvG Original Publication: Houten : Bohn Stafleu van Loghum |
| مواضيع طبية MeSH: | Antibodies, Monoclonal/*pharmacokinetics , Immunologic Factors/*pharmacokinetics, Absorption ; Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Routes ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/therapeutic use ; Mice ; Molecular Weight |
| مستخلص: | Monoclonal antibodies (MOABs) are, due to their specificity, increasingly being deployed for therapeutic purposes. MOABs are derived from immunoglobulins and are fully or partially of murine or human origin. They are administered parenterally: mostly intravenously, but subcutaneous or intramuscular administration is also possible, in which case absorption probably occurs through the lymphatic system. The distribution of MOABs from the bloodstream into the tissues is slow and is hampered by the high molecular size of the MOABs, which is a lesser problem for fragments of antibodies (Fab fragments). MOABs are metabolised to peptides and amino acids. This process takes place in many tissues of the body, but probably predominantly in epithelial cells. As a consequence of the saturable binding of the MOAB to its target, a dose-dependent (non-linear) elimination is often observed. Immune reactions can accelerate the elimination of antibodies, partially depending on the degree ofhumanisation of the antibody. Antibodies and endogenous immunoglobulins are protected from elimination by binding to protective receptors (neonatal Fc-receptor; FcRn), which explains their long half-lives (up to 4 weeks). Metabolic pharmacokinetic interactions with other drugs have not been reported and are not expected. It is expected that in the years to come, new MOABs directed towards new targets will appear on the market, as well as existing antibodies with improved pharmacokinetic properties. |
| Number of References: | 26 |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20070424 Date Completed: 20070515 Latest Revision: 20070423 |
| رمز التحديث: | 20240513 |
| PMID: | 17447593 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0028-2162 |
|---|